Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension

Journal of Human Hypertension

Volumn 13, Issue SUPPL. 1, 1999, Pages

  Higashiura, Katsuhiro ^a   Ura, N ^a   Miyazaki, Y ^a   Shimamoto, K ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II receptor antagonist; Candesartan; Essential hypertension; Insulin resistance

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; SODIUM ION;

ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; PRESSOR RESPONSE; SODIUM RETENTION;

EID: 0032959857     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000748     Document Type: Conference Paper

References (20)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
2. Kaplan NM. The deadly quartet. Upperbody obesity, glucose intolerance in hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514-1520.
3. DeFronzo RA, Ferrannini E, Insulin resistance - A multifactorial syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
4. Modan M et al. Hyperinsulinemia, sex and risk of atherosclerotic cardiovascular disease. Circulation 1991; 84: 1165-1175.
5. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Eng J Med 1989; 321: 868-873.
6. Pollare T et al. Metabolic effects of diltiazem and ate-olol: results from a randomized, double-blind study with parallel groups. J Hypertens 1989; 7: 551-559.
7. Ferrannini E et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 316: 350-355.
8. Alkharouf J et al. Long-term effects of the angiotensin converting enzyme inhibitor captopril on metabolic control in noninsulin dependent diabetes mellitus. Am J Hypertens 1993; 6: 337-343.
9. Paolisso G et al. Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. J Hum Hypertens 1997; 11: 307-312.
10. Moan A et al. The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. Blood Press 1994; 3: 185-188.
11. Moan A et al. The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. J Hypertens 1996; 14: 1093-1097.
12. Laakso M, Kajakainen L, Lempiainen-Kuosa P. Effects of losartan on insulin sensitivity in hypertensive subjects. Hypertension 1996; 28: 392-396.
13. DeFronzo RA, Tobian JD, Anders R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237(3): E214-E223.
14. Baron AD et al. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest 1995; 96: 786-792.
15. Lillipja S et al. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in men. J Clin Invest 1987; 80: 415-424.
16. Kahn BB et al. Decreased in vivo glucose uptake but normal expression of GLUT 1 and GLUT 4 in skeletal muscle of diabetic rats. J Clin Invest 1991; 84: 2197-2206.
17. Hoenack C, Roesen P. Inhibition of angiotensin type I receptor prevents decline in glucose transporters in diabetic rat hearts. Diabetes 1996; 45 (Suppl 1): S82-S87.
18. Shimamoto K et al. Insulin sensitivity and the effects of insulin on renal sodium handling and pressor systems in essential hypertensive patients. Hypertension 1994; 23 (Suppl I): 129-133.
19. Houston MC. The effects of antihypertensive drugs on glucose intolerance in hypertensive nondiabetics. Am Heart J 1988; 115: 640-656.
20. Stumpe KO. Antihypertensive therapy: new strategies beyond blood pressure control. J Cardiovasc Pharmacol 1992; 20 (Suppl 6): S1-S4.